يعرض 1 - 6 نتائج من 6 نتيجة بحث عن '"J T Isakova"', وقت الاستعلام: 0.66s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية

    المصدر: Malignant tumours; Том 8, № 4 (2018); 45-49 ; Злокачественные опухоли; Том 8, № 4 (2018); 45-49 ; 2587-6813 ; 2224-5057

    وصف الملف: application/pdf

    العلاقة: https://www.malignanttumors.org/jour/article/view/585/405Test; Sieber O. M., Heinimann K., Tomlinson I. P. Genomic instability – the engine of tumorigenesis? Nat. Rev. Cancer. 2003. Vol. 3. P. 701–708.; Sultana R., Abdel-Fatah T., Abbotts R., Hawkes C., Albarakati N. Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy. Cancer Res. 2013. Vol. 73 (5). P. 1621–1634. DOI:10.1158 / 0008‑5472.CAN-12‑2929 2013.; Ladiges W. C. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene. 2006. Vol. 25. P. 1612–1619.; Horton J. K., Watson M., Stefanick D. F., Shaughnessy D. T., Taylor J. A., Wilson S. H. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008. Vol. 18. P. 48–63.; Zhang R., Niu Y., Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol. Lett. 2010. Vol. 192. P. 108–114.; Tischkowitz M., Xia B., Sabbaghian N. et al. Analysis of PALB2 / FANCN-associated breast cancer families. Proc. Natl. Acad. Sci. USA. 2007. Vol. 104. P. 6788–6793.; Rahman N., Seal S., Thompson D., Kelly P., Renwick A., Elliott A., Reid S., Spanova K., Barfoot R., Chagtai T. et al. PALB2, which encodes a BRCA2‑interacting protein, is a breast cancer susceptibility gene. Cancer. 2007. Vol. 39. P. 165–167.; Akent’eva N. P., Shushanov S. S., Kotelnikov A. I. Effects of RHAAM / HMMR – selective peptides on survival of breast cancer cells. Bulletin of Experimental Biology and Medicine. 2015. Vol. 159. No. 5. P. 658–661.; Lejeune F. J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 1998. Vol. 10. P. 573–580.; Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001. Vol. 357. P. 539–545; Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Res. 2002. Vol. 13. P. 135–141.; Leek R. D., Landers R., Fox S. B., Ng F., Harris A. L. et al. (1998) Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Brit. J. Cancer. 1998. Vol. 77. P. 2246–2251.; https://www.malignanttumors.org/jour/article/view/585Test

  4. 4
  5. 5
    دورية أكاديمية

    المصدر: PULMONOLOGIYA; № 3 (2008); 64-66 ; Пульмонология; № 3 (2008); 64-66 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2008-0-3

    وصف الملف: application/pdf

    العلاقة: https://journal.pulmonology.ru/pulm/article/view/1814/1313Test; Фармер П.Е., Кононец Ф.С., Борисов С.Е. и др. Полирезистентный туберкулез: угроза человечеству. М.; 1999.; Михайлович В.М., Лапа С.А., Грядунов Д.А. и др. Использование методов гибридизации и ПЦР на специализированном ТБ-микрочипе для обнаружения рифампицин резистентных штаммов Mycobacterium tuberculosis. Бюл. экспер. биол. 2001; 1: 112–117.; Crofton J., Chaulet P., Maher D. Guidelines for the Management of Drug-Resistant Tuberculosis. Geneva; 1997.; Пресс-релиз ВОЗ/17. Европейское региональное бюро ВОЗ. Женева; 2004.; Maher D., Chaulet P., Spinaci S., Harries A. Treatment of tuberculosis: Guidelines for national programmes. 2nd ed. Geneva: World Health Organisation; 1997.; Mikhailovich V., Lapa S., Grydunov D. et al. Identification of rifampin-resistant mycobacterium tuberculosis strains by hybridization, PCR, and ligase detection reaction on oligonucleotide microchips. J. Clin. Microbiol. 2001; 39: 2531–2540.; https://journal.pulmonology.ru/pulm/article/view/1814Test

  6. 6